Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TEN-010 |
Trade Name | |
Synonyms | RG-6146|JQ2|RO6870810|RG6146|RO-6870810 |
Drug Descriptions |
RO6870810 (TEN-010) binds to the bromodomain of BET proteins preventing their interaction with acetylated histone peptides, thus disrupting chromatin remodeling, gene expression, and cell proliferation (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A49). |
DrugClasses | BET Inhibitor (Pan) 32 |
CAS Registry Number | 1349719-98-7 |
NCIT ID | C112500 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + TEN-010 | Atezolizumab TEN-010 | 0 | 1 |
Daratumumab + TEN-010 | Daratumumab TEN-010 | 0 | 1 |
Rituximab + TEN-010 + Venetoclax | Rituximab TEN-010 Venetoclax | 0 | 1 |
TEN-010 | TEN-010 | 0 | 3 |